22nd IMS Annual Meeting
Mark your calendars for the 22nd IMS Annual Meeting in Toronto, Canada.
The International Myeloma Society Meeting is the defining annual meeting in myeloma with a focus on both the basic, preclinical, and clinical aspects.
This year’s program includes:
- Four thematic sessions on:
- Precursor Disease
- Risk Adaptation Management
- Immunotherapy
- Relapse within 1-3 lines of therapy
- Talks and symposia on pressing topics led by the KOL of the myeloma community
- Keynote addresses
- Joint sessions with regulatory agencies and other organisations
- Meet the Expert sessions
- Oral Abstracts (on Basic Biology, Preclinical Trials, and Clinical Studies)
- Poster presentations and discussion sessions
Our sponsors:
Titanium
Platinum
Silver
Bronze
Relapsed/Refractory Multiple Myeloma Webinar – East Coast
This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for RRMM patients including treating early relapse and late relapse with high risk patients. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.
Program
Relapsed/Refractory Multiple Myeloma Webinar – West Coast
This high-impact, 90-minute educational program will focus on the latest evidence for optimizing treatments for RRMM patients including treating early relapse and late relapse with high risk patients. Key concepts will be covered in presentations by senior faculty, along with practice-relevant case-based discussions.
Program
Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma 2025
Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!
This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.
Preliminary Agenda
Our sponsors:
Platinum
Gold
7th Immune Effector Cell Therapies in Multiple Myeloma Workshop
IMS is pleased to announce that the 7th Annual Immune Effector Cell will take place from March 27-28, 2026 in Boston, MA.
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
